Drug Trial Radar · NCT07745907
A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
28
Planned (sponsor's estimate)
Start
Aug 7, 2026
Primary completion
Mar 17, 2027
Study completion Mar 17, 2027
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Aug 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The trial is designed to evaluate the pharmacokinetics, safety, tolerability, and immunogenicity of AMG 691 in healthy Chinese and Japanese participants
Conditions
- Healthy Participants
Interventions
AMG 691Drug
AMG 691 will be administered subcutaneously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Serum Concentration (Cmax) of AMG 691Time frame: Day 1 up to Day 154
- Area Under the Serum Concentration Time Curve (AUC) from Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of AMG 691Time frame: Up to Day 154
- Area Under the Serum concentration Time Curve from Time Zero to Infinity (AUC0-inf) of AMG 691Time frame: Up to Day 154
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PPD - Las Vegas Research Unit
Las Vegas, Nevada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.